

A 37

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
15 May 2003 (15.05.2003)

PCT

(10) International Publication Number  
WO 03/039550 A1

- (51) International Patent Classification<sup>7</sup>: A61K 31/506, A61P 17/00, 35/00, 43/00, A61K 7/48
- (21) International Application Number: PCT/IB02/04330
- (22) International Filing Date:  
20 September 2002 (20.09.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/323,312 20 September 2001 (20.09.2001) US
- (71) Applicant (for all designated States except US): AB SCI-ENCE [FR/FR]; 3, avenue Georges V, F-75008 Paris (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): MOUSSY, Alain [FR/FR]; 22 bis, Passage Dauphine, F-75006 Paris (FR). KINET, Jean-Pierre [FR/US]; 3 Hunt Road, Lexington, MA 02421 (US).
- (74) Agents: MARTIN, Jean-Jacques et al.; Cabinet Regim-beau, 20, Rue de Chazelles, F-75847 Paris Cedex 17 (FR).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only
- Published:**
- with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF TYROSINE KINASE INHIBITORS FOR WHITENING HUMAN SKIN AND TREATING MELANOCYTE DYSFUNCTION ASSOCIATED DISEASES

(57) Abstract: The present invention relates to a method for whitening human skin and treating melanocyte dysfunction associated diseases comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

WO 03/039550 A1

WO 03/039550

PCT/IB02/04330

I

**Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases**

5

The present invention relates to a method for whitening human skin and treating melanocyte dysfunction associated diseases comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3  
10 dependent cells cultured in presence of IL-3.

The skin consists of two layers, the epidermis and the underlying dermis, which are separated by the basal membrane. Melanocytes are found in the basal layer and exhibit generally globular cellular morphologies with numerous dendritic ramifications. These  
15 highly specialized cells penetrate the neighboring keratinocytes of the basal layer. Melanocytes have melanosomes, which produces the melanin pigments. Melanosomes are released from the melanocyte dendrites onto the surroundings of neighboring cells, thereby diffusing pigmentation across the skin.

20 Melanosomes produces melanin thanks to tyrosinase, which catalyzes the conversion of L-tyrosine to L-dihydroxyphenylalanine (L-Dopa), which is a melanin precursor. The melanosomes migrate from the Golgi apparatus through the cell body and into the dendrites, in the process accumulating melanin. At last, melanin serves as a natural solar filter, absorbing over 90% of the UV radiation passing through the horny layer of skin,  
25 thereby protecting DNA from UV-induced modification.

WO 03/039550

PCT/IB02/04330

2

Skin pigmentation is directly proportional to the quantity of melanocytes in the skin. Hyperpigmentation patterns can reflect concentrations of correctly proliferating melanocytes, or the results of improper proliferation. The former category of hyperpigmentation include freckles, chloasma (a hypersecretion of melanin induced by hormonal factors and amplified by the effects of the sun), and various forms of hypermelanosis. Other excessive skin pigmentation resulting from melanocyte dysfunction include lentigines, solar and senile lentigo, Dubreuilh melanosis (a precancerous condition), moles and malignant melanomas.

10 In Asia and other parts of the world, women may desire whiter skin because of traditional beliefs that white skin denotes nobility and beauty. Thus, in recent years, cosmetic compositions have been developed to reduce the amount of melanin in the skin and therefore, whiten the skin.

15 As a result, there is real need in the development of cosmetic and clinical treatments for whitening the skin.

In the past, chemicals used to whiten skin, such as hydrogen peroxide, mercurialized amide chlorate, mercaptoamines and phenol derivatives such as hydroquinone irritate the skin. Modern compositions are more selective in their effects and better tolerated. Indeed, research has focused on whitening agents that inhibit the activity of tyrosinase, which plays a key role in the biosynthesis of melanin. For example, it has been proposed to incorporate into cosmetic compositions tyrosinase inhibitors such as hydroquinone, vitamin C and its derivatives, kojic acid, arbutin, glutathione, cysteine as well as plant  
25 extracts (US 5,773,014 and US 5,980,904).

WO 03/039550

PCT/IB02/04330

3

However, tyrosinase inhibitors such as kojic acid, ascorbic acid and their derivatives are unstable in cosmetic preparations and their rapid oxidation decreases tyrosinase inhibition and results in the black coloration of the preparations. Moreover, although less cytotoxic than phenol derivatives, tyrosinase inhibitors exhibit unwanted side effects.

5

As a result, alternative solutions are required for whitening human skin without causing irritation and toxicity to the epidermis and underlying dermis. Advantageously, it is of special interest to provide a composition which is effective for the treatment of melanocyte dysfunction related diseases leading to hyperpigmentation.

10

Grichnik et al, J Invest Dermatol 1998 Aug;111(2):233-8 have demonstrated that the SCF/KIT pathway is implicated in the control of normal human melanocyte homeostasis. On histologic evaluation, SCF injection increased the number, size, and dendricity of melanocytes.

15

In connection with the present invention, it is proposed to use specific kinase inhibitors to inhibit the SCF/KIT pathway which is responsible for melanocytes proliferation. It has been found that tyrosine kinase inhibitors and more particularly c-kit inhibitors are especially suited to reach this goal. Furthermore, activating mutations in the c-kit receptor is postulated to induce abnormal proliferation of melanocytes leading to the formation of melanomas.

20

Such inhibitors are not only useful for whitening the skin but they are good candidate for treating hypermelanosis resulting from melanocyte dysfunction and including lentigines, solar and senile lentigo, Dubreuilh melanosis, moles as well as malignant melanomas.

25

WO 03/039550

PCT/IB02/04330

4

5

**Description**

The present invention relates to a method for whitening human skin and treating melanocyte dysfunction associated diseases comprising administering a tyrosine kinase inhibitor to a human in need of such treatment.

Tyrosine kinase inhibitors are selected for example from bis monocyclic, bicyclic or heterocyclic aryl compounds (WO 92/20642), vinylene-azaindole derivatives (WO 94/14808) and 1-cyclopropyl-4-pyridyl-quinolones (US 5,330,992), Styryl compounds (US 5,217,999), styryl-substituted pyridyl compounds (US 5,302,606), seleoindoles and selenides (WO 94/03427), tricyclic polyhydroxylic compounds (WO 92/21660) and benzylphosphonic acid compounds (WO 91/15495), pyrimidine derivatives (US 5,521,184 and WO 99/03854), indolinone derivatives and pyrrol-substituted indolinones (US 5,792,783, EP 934 931, US 5,834,504, US 5,883,116, US 5,883,113, US 5,886,020, WO 96/40116 and WO 00/38519), as well as bis monocyclic, bicyclic aryl and heteroaryl compounds (EP 584 222, US 5,656,643 and WO 92/20642), quinazoline derivatives (EP 602 851, EP 520 722, US 3,772,295 and US 4,343,940) and aryl and heteroaryl quinazoline (US 5,721,237, US 5,714,493, US 5,710,158 and WO 95/15758).

Preferably, said tyrosine kinase inhibitors are unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

In another embodiment, the invention is directed to a method for whitening human skin and treating melanocyte dysfunction associated diseases comprising administering a c-kit inhibitor to a human in need of such treatment.

WO 03/039550

PCT/IB02/04330

5

Preferably, said c-kit inhibitor is a non-toxic, selective and potent c-kit inhibitor. Such inhibitors can be selected from the group consisting of indolinones, pyrimidine derivatives, pyrrolopyrimidine derivatives, quinazoline derivatives, quinoxaline derivatives, pyrazoles derivatives, bis monocyclic, bicyclic or heterocyclic aryl  
5 compounds, vinylene-azaindole derivatives and pyridyl-quinolones derivatives, styryl compounds, styryl-substituted pyridyl compounds, seleoindoles, selenides, tricyclic polyhydroxylic compounds and benzylphosphonic acid compounds.

Among preferred compounds, it is of interest to focus on pyrimidine derivatives such as  
10 N-phenyl-2-pyrimidine-amine derivatives (US 5,521,184 and WO 99/03854), indolinone derivatives and pyrrol-substituted indolinones (US 5,792,783, EP 934 931, US 5,834,504), US 5,883,116, US 5,883,113, US 5, 886,020, WO 96/40116 and WO 00/38519), as well as bis monocyclic, bicyclic aryl and heteroaryl compounds (EP 584 222, US 5,656,643 and WO 92/20642), quinazoline derivatives (EP 602 851, EP 520  
15 722, US 3,772,295 and US 4,343,940), 4-amino-substituted quinazolines (US 3,470,182), 4-thienyl-2-(1H)-quinazolones, 6,7-dialkoxyquinazolines (US 3,800,039), aryl and heteroaryl quinazoline (US 5,721,237, US 5,714,493, US 5,710,158 and WO 95/15758), 4-anilinoquinazoline compounds (US 4,464,375), and 4-thienyl-2-(1H)-quinazolones (US 3,551,427).


20

So, preferably, the invention relates to a method for whitening human skin and treating melanocyte dysfunction associated diseases comprising administering a non toxic, potent and selective c-kit inhibitor which is a pyrimidine derivative, more particularly N-phenyl-2-pyrimidine-amine derivatives of formula I :

WO 03/039550


PCT/IB02/04330

6




wherein the R1, R2, R3, R13 to R17 groups have the meanings depicted in EP 564 409 B1, incorporated herein in the description.

- 5 Preferably, the N-phenyl-2-pyrimidine-amine derivative is selected from the compounds corresponding to formula II :



- 10 Wherein R1, R2 and R3 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl or a cyclic or heterocyclic group, especially a pyridyl group;  
 R4, R5 and R6 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl, especially a methyl group;  
 and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least  
 15 one basic site, such as an amino function.

Preferably, R7 is the following group :



WO 03/039550

PCT/IB02/04330

7

Among these compounds, the preferred are defined as follows:


R1 is a heterocyclic group, especially a pyridyl group,

R2 and R3 are H,

5 R4 is a C1-C3 alkyl, especially a methyl group,

R5 and R6 are H,


and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function, for example the group :



10

Therefore, in a preferred embodiment, the invention relates to a method for whitening human skin and treating melanocyte dysfunction associated diseases comprising the administration of an effective amount of the compound known in the art as CGP57148B :

15 4-(4-méthylpipérazine-1-ylméthyl)-N-[4-méthyl-3-(4-pyridine-3-yl)pyrimidine-2-ylamino]phényl]-benzamide corresponding to the following formula :



20 The preparation of this compound is described in example 21 of EP 564 409 and the  $\beta$ -form, which is particularly useful is described in WO 99/03854.

Alternatively, the c-kit inhibitor can be selected from :



WO 03/039550

PCT/IB02/04330

8

- indolinone derivatives, more particularly pyrrol-substituted indolinones,
- monocyclic, bicyclic aryl and heteroaryl compounds, quinazoline derivatives,
- and quinaxolines, such as 2-phényl-quinaxoline derivatives, for example 2-phenyl-6,7-dimethoxy quinaxoline.

5

In a preferred aspect, the invention contemplated the method mentioned above, wherein said c-kit inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

- 10 In a further embodiment, c-kit inhibitors as mentioned above are inhibitors of activated c-kit. In frame with the invention, the expression "activated c-kit" means a constitutively activated-mutant c-kit including at least one mutation selected from point mutations, deletions, insertions, but also modifications and alterations of the natural c-kit sequence (SEQ ID N°1). Such mutations, deletions, insertions, modifications and alterations can
- 15 occur in the transphosphorylase domain, in the juxtamembrane domain as well as in any domain directly or indirectly responsible for c-kit activity. The expression "activated c-kit" also means herein SCF-activated c-kit. Preferred and optimal SCF concentrations for activating c-kit are comprised between  $5.10^{-7}$  M and  $5.10^{-6}$  M, preferably around  $2.10^{-6}$  M. In a preferred embodiment, the activated-mutant c-kit in step a) has at least one
- 20 mutation proximal to Y823, more particularly between amino acids 800 to 850 of SEQ ID No1 involved in c-kit autophosphorylation, notably the D816V, D816Y, D816F and D820G mutants. In another preferred embodiment, the activated-mutant c-kit in step a) has a deletion in the juxtamembrane domain of c-kit. Such a deletion is for example between codon 573 and 579 called c-kit d(573-579). The point mutation V559G
- 25 proximal to the juxtamembrane domain c-kit is also of interest.

In this regard, the invention contemplates a method for whitening human skin and treating melanocyte dysfunction associated diseases comprising administering to a

WO 03/039550

PCT/IB02/04330

9

mammal in need of such treatment a compound that is a selective, potent and non toxic inhibitor of activated c-kit obtainable by a screening method which comprises :

- a) bringing into contact (i) activated c-kit and (ii) at least one compound to be tested; under conditions allowing the components (i) and (ii) to form a complex,
- 5 b) selecting compounds that inhibit activated c-kit,
- c) testing and selecting a subset of compounds identified in step b), which are unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

This screening method can further comprise the step consisting of testing and selecting a  
10 subset of compounds identified in step b) that are inhibitors of mutant activated c-kit (for example in the transphosphorylase domain), which are also capable of inhibiting SCF-activated c-kit wild.

Alternatively, in step a) activated c-kit is SCF-activated c-kit wild.

- 15 A best mode for practicing this method consists of testing putative inhibitors at a concentration above 10  $\mu$ M in step a). Relevant concentrations are for example 10, 15, 20, 25, 30, 35 or 40  $\mu$ M.

In step c), IL-3 is preferably present in the culture media of IL-3 dependent cells at a  
20 concentration comprised between 0.5 and 10 ng/ml, preferably between 1 to 5 ng/ml.

Examples of IL-3 dependent cells include but are not limited to :

- cell lines naturally expressing and depending on c-kit for growth and survival. Among such cells, human mast cell lines can be established using the following procedures :
- 25 normal human mast cells can be infected by retroviral vectors containing sequences coding for a mutant c-kit comprising the c-kit signal peptide and a TAG sequence allowing to differentiate mutant c-kits from c-kit wild expressed in hematopoietic cells by means of antibodies.

WO 03/039550

PCT/IB02/04330

10

This technique is advantageous because it does not induce cellular mortality and the genetic transfer is stable and gives satisfactory yields (around 20 %). Pure normal human mast cells can be routinely obtained by culturing precursor cells originating from blood obtained from human umbilical vein. In this regard, heparinated blood from umbilical  
5 vein is centrifuged on a Ficoll gradient so as to isolate mononucleated cells from other blood components. CD34+ precursor cells are then purified from the isolated cells mentioned above using the immunomagnetic selection system MACS (Miltenyi biotech). CD34+ cells are then cultured at 37°C in 5 % CO<sub>2</sub> atmosphere at a concentration of 10<sup>5</sup> cells per ml in the medium MCCM ( $\alpha$ -MEM supplemented with L-glutamine, penicillin,  
10 streptomycin, 5 10<sup>-5</sup> M  $\beta$ -mercaptoethanol, 20 % veal foetal serum, 1 % bovine albumin serum and 100 ng/ml recombinant human SCF. The medium is changed every 5 to 7 days. The percentage of mast cells present in the culture is assessed each week, using May-Grünwal Giemsa or Toluidine blue coloration. Anti-tryptase antibodies can also be used to detect mast cells in culture. After 10 weeks of culture, a pure cellular population  
15 of mast cells (> 98 %) is obtained.

It is possible using standard procedures to prepare vectors expressing c-kit for transfecting the cell lines established as mentioned above. The cDNA of human c-kit has been described in Yarden et al., (1987) EMBO J.6 (11), 3341-3351. The coding part of c-kit (3000 bp) can be amplified by PCR and cloned, using the following  
20 oligonucleotides :

- 5'AAGAAGAGATGGTACCTCGAGGGGTGACCC3' (SEQ ID No2) sens
- 5'CTGCTTCGCGGCCGCGTTAACTCTTCTCAACCA3' (SEQ ID No3) antisens

The PCR products, digested with NotI and XhoI, has been inserted using T4 ligase in  
25 the pFlag-CMV vector (SIGMA), which vector is digested with NotI and XhoI and

WO 03/039550

PCT/IB02/04330

11

dephosphorylated using CIP (Biolabs). The pFlag-CMV-c-kit is used to transform bacterial clone XLI-blue. The transformation of clones is verified using the following primers :

- 5'AGCTCGTTTAGTGAACCGTC3' (SEQ ID No4) sens,
- 5 - 5'GTCAGACAAAATGATGCAAC3' (SEQ ID No5) antisens.

Directed mutagenesis is performed using relevant cassettes is performed with routine and common procedure known in the art..

The vector Migr-1 (ABC) can be used as a basis for constructing retroviral vectors used for transfecting mature mast cells. This vector is advantageous because it contains the sequence coding for GFP at the 3' and of an IRES. These features allow to select cells infected by the retrovirus using direct analysis with a fluorocytometer. As mentioned above, the N-terminal sequence of c-kit c-DNA can be modified so as to introduce a Flag sequence that will be useful to discriminating heterogeneous from endogenous c-kit.

15 Other IL-3 dependent cell lines that can be used include but are not limited to:

- BaF3 mouse cells expressing wild-type or mutated form of c-kit (in the juxtamembrane and in the catalytic sites) are described in Kitayama et al, (1996), Blood 88, 995-1004 and Tsujimura et al, (1999), Blood 93, 1319-1329.
- IC-2 mouse cells expressing either c-kit<sup>WT</sup> or c-kit<sup>D814Y</sup> are presented in Piao et al, 20 (1996), Proc. Natl. Acad. Sci. USA 93, 14665-14669.

IL-3 independent cell lines are :

- HMC-1, a factor-independent cell line derived from a patient with mast cell leukemia, expresses a juxtamembrane mutant c-kit polypeptide that has constitutive kinase activity 25 (Furitsu T et al, J Clin Invest. 1993;92:1736-1744 ; Butterfield et al, Establishment of an

WO 03/039550

PCT/IB02/04330

12

immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12:345-355 and Nagata et al, Proc Natl Acad Sci U S A. 1995;92:10560-10564).

- P815 cell line (mastocytoma naturally expressing c-kit mutation at the 814 position) has been described in Tsujimura et al, (1994), Blood 83, 2619-2626.

5

The extent to which component (ii) inhibits activated c-kit can be measured *in vitro* or *in vivo*. In case it is measured *in vivo*, cell lines expressing an activated-mutant c-kit, which has at least one mutation proximal to Y823, more particularly between amino acids 800 to 850 of SEQ ID No1 involved in c-kit autophosphorylation, notably the D816V,  
10 D816Y, D816F and D820G mutants, are preferred.

Example of cell lines expressing an activated-mutant c-kit are as mentioned.

In another preferred embodiment, the method further comprises the step consisting of testing and selecting compounds capable of inhibiting c-kit wild at concentration below  
15 1  $\mu$ M. This can be measured *in vitro* or *in vivo*.

Therefore, compounds are identified and selected according to the method described above are potent, selective and non-toxic c-kit wild inhibitors.

20 Alternatively, the screening method as defined above can be practiced *in vitro*. In this regard, the inhibition of mutant-activated c-kit and/or c-kit wild can be measured using standard biochemical techniques such as immunoprecipitation and western blot. Preferably, the amount of c-kit phosphorylation is measured.

25 In a still further embodiment, the invention contemplates a method for whitening human skin and treating melanocyte dysfunction associated diseases as depicted above wherein the screening comprises :

WO 03/039550

PCT/IB02/04330

13

- a) performing a proliferation assay with cells expressing a mutant c-kit (for example in the transphosphorylase domain), which mutant is a permanent activated c-kit, with a plurality of test compounds to identify a subset of candidate compounds targeting activated c-kit, each having an  $IC_{50} < 10 \mu M$ , by measuring the extent of cell death,
- 5 b) performing a proliferation assay with cells expressing c-kit wild said subset of candidate compounds identified in step (a), said cells being IL-3 dependent cells cultured in presence of IL-3, to identify a subset of candidate compounds targeting specifically c-kit,
- c) performing a proliferation assay with cells expressing c-kit, with the subset of
- 10 compounds identified in step b) and selecting a subset of candidate compounds targeting c-kit wild, each having an  $IC_{50} < 10 \mu M$ , preferably an  $IC_{50} < 1 \mu M$ , by measuring the extent of cell death.

Here, the extent of cell death can be measured by  $^3H$  thymidine incorporation, the trypan

15 blue exclusion method or flow cytometry with propidium iodide. These are common techniques routinely practiced in the art.

The expression "melanocyte dysfunction associated diseases" will be understood herein as hypermelanosis resulting from melanocyte dysfunction and including lentigines, solar

20 and senile lentigo, Dubreuilh melanosis, moles as well as melanomas including malignant melanomas.

Therefore, the invention embraces the use of the compounds defined above to manufacture a medicament or a cosmetic composition for whitening human skin and

25 treating melanocyte dysfunction associated diseases as defined above.

The pharmaceutical or cosmetic compositions utilized in this invention may be administered by any number of routes including oral and topical.

WO 03/039550

PCT/IB02/04330

14

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may  
5 be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral  
10 administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical compositions suitable for use in the invention include compositions  
15 wherein c-kit inhibitors are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or  
20 experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. As mentioned above, a tyrosine kinase inhibitor and more particularly a c-kit  
25 inhibitor according to the invention is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

WO 03/039550

PCT/IB02/04330

15

Preferably, the method according to the invention consists of applying to the skin a composition comprising an effective amount of a tyrosine kinase inhibitor as depicted above and a carrier acceptable for external use.

- 5 Thus, the invention also concerns a pharmaceutical or cosmetic composition for topical administration comprising a tyrosine kinase inhibitor and optionally at least one compound selected from the group consisting of tyrosinase inhibitors as mentioned above.
- 10 The compositions according to the invention may be presented in all forms normally used for topical application, in particular in the form of a gel, paste, ointment, cream, lotion, liquid suspension aqueous, aqueous-alcoholic or, oily solutions, or dispersions of the lotion or serum type, or anhydrous or lipophilic gels, or emulsions of liquid or semi-solid consistency of the milk type, obtained by dispersing a fatty phase in an aqueous
- 15 phase or vice versa, or of suspensions or emulsions of soft, semi-solid consistency of the cream or gel type, or alternatively of microemulsions, of microcapsules, of microparticles or of vesicular dispersions to the ionic and/or nonionic type. These compositions are prepared according to standard methods.
- 20 The composition according to the invention comprises any ingredient commonly used in dermatology and cosmetic. It may comprise at least one ingredient selected from hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, emollients, viscosity enhancing polymers, humectants, surfactants, preservatives, antioxidants, solvents, and fillers, antioxidants, solvents, perfumes, fillers,
- 25 screening agents, bactericides, odor absorbers and coloring matter.

As oils which can be used in the invention, mineral oils (liquid paraffin), vegetable oils (liquid fraction of shea butter, sunflower oil), animal oils, synthetic oils, silicone oils



WO 03/039550

PCT/IB02/04330

16

(cyclomethicone) and fluorinated oils may be mentioned. Fatty alcohols, fatty acids (stearic acid) and waxes (paraffin, carnauba, beeswax) may also be used as fatty substances.

5 As emulsifiers which can be used in the invention, glycerol stearate, polysorbate 60 and the PEG-6/PEG-32/glycol stearate mixture are contemplated.

As hydrophilic gelling agents, carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, clays and natural gums may be mentioned, and as lipophilic  
10 gelling agents, modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, or alternatively ethylcellulose and polyethylene may be mentioned.

As hydrophilic active agents, proteins or protein hydrolysates, amino acids, polyols,  
15 urea, allantoin, sugars and sugar derivatives, vitamins, starch and plant extracts, in particular those of Aloe vera may be used.

As lipophilic active agents, retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides and essential oils may be used.

20 These agents add extra moisturizing or skin softening features when utilized.

If desired, a known gelling agent may be added to the composition of the invention. Suitable gelling agents include a synthetic high molecular weight crosslinked polymer of acrylic acid, more specifically an acrylate/C.sub.10-30 alkyl acrylate copolymer available  
25 for example under the trade name CARBOMER 1342. Other suitable gelling agents include cellulose and cellulose derivatives such as dihydroxyethyl cellulose (tradename ULTRAGEL).

WO 03/039550

PCT/IB02/04330

17

In addition, a surfactant can be included in the composition so as to provide deeper penetration of the ingredients and of the tyrosine kinase inhibitor.

Among the contemplated ingredients, the invention embraces penetration enhancing agents selected for example from the group consisting of mineral oil, water, ethanol, triacetin, glycerin and propylene glycol; cohesion agents selected for example from the group consisting of polyisobutylene, polyvinyl acetate and polyvinyl alcohol, and thickening agents.

10 Chemical methods of enhancing topical absorption of drugs are well known in the art. For example, compounds with penetration enhancing properties include sodium lauryl sulfate (Dugard, P. H. and Sheuplein, R. J., "Effects of Ionic Surfactants on the Permeability of Human Epidermis: An Electrometric Study," J. Invest. Dermatol., V.60, pp. 263-69, 1973), lauryl amine oxide (Johnson et. al., US 4,411,893), azone  
15 (Rajadhyaksha, US 4,405,616 and 3,989,816) and decylmethyl sulfoxide (Sekura, D. L. and Scala, J., "The Percutaneous Absorption of Alkylmethyl Sulfides," Pharmacology of the Skin, Advances In Biology of Skin, (Appleton-Century Craft) V. 12, pp. 257-69, 1972). It has been observed that increasing the polarity of the head group in amphoteric molecules increases their penetration-enhancing properties but at the expense of  
20 increasing their skin irritating properties (Cooper, E. R. and Berner, B., "Interaction of Surfactants with Epidermal Tissues: Physiochemical Aspects," Surfactant Science Series, V. 16, Reiger, M. M. ed. (Marcel Dekker, Inc.) pp. 195-210, 1987).

Suitable solvents include alkyl esters of fatty acids, preferably C.sub.1-12, more  
25 preferably C.sub.3-10, alkyl esters of saturated or unsaturated fatty acids containing 8-22 carbon atoms. Particularly preferred solvents include isopropyl myristate, octyl palmitate, WIKENOL 161 (a mixture of esters), etc. Alcohols such as ethanol, propanol,

WO 03/039550

PCT/IB02/04330

18

isopropanol, propylene glycol, etc., as well as aqueous mixtures of these alcohols may also be used.

A second class of chemical enhancers are generally referred to as co-solvents. These materials are absorbed topically relatively easily, and, by a variety of mechanisms, achieve permeation enhancement for some drugs. Ethanol (Gale et. al., U.S. Pat. No. 4,615,699 and Campbell et. al., U.S. Pat. Nos. 4,460,372 and 4,379,454), dimethyl sulfoxide (US 3,740,420 and 3,743,727, and US 4,575,515), and glycerine derivatives (US 4,322,433) are a few examples of compounds which have shown an ability to enhance the absorption of various compounds.

The invention is aimed at a composition which is formulated for the delivery of the tyrosine kinase inhibitor to the skin whether it is a cosmetic or dermatologic composition.

15

WO 03/039550

PCT/IB02/04330

19

**CLAIMS**

- 5
1. A method for whitening human skin and treating melanocyte dysfunction associated diseases, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment.
  - 10 2. A method according to claim 1, wherein said tyrosine kinase inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
  3. A method for whitening human skin and treating melanocyte dysfunction associated diseases, comprising administering a c-kit inhibitor to a human in need of such
  - 15 treatment.
  4. A method according to claim 3, wherein said c-kit inhibitor is a non-toxic, selective and potent c-kit inhibitor.
  - 20 5. A method according to claim 4, wherein said inhibitor is selected from the group consisting of indolinones, pyrimidine derivatives, pyrrolopyrimidine derivatives, quinazoline derivatives, quinoxaline derivatives, pyrazoles derivatives, bis monocyclic, bicyclic or heterocyclic aryl compounds, vinylene-azaindole derivatives and pyridyl-quinolones derivatives, styryl compounds, styryl-substituted pyridyl compounds,
  - 25 seleoindoles, selenides, tricyclic polyhydroxylic compounds and benzylphosphonic acid compounds.

WO 03/039550

PCT/IB02/04330


20

6. A method according to claim 4, wherein said inhibitor is selected from the group consisting of :

- pyrimidine derivatives, more particularly N-phenyl-2-pyrimidine-amine derivatives.
- indolinone derivatives, more particularly pyrrol-substituted indolinones,
- 5 - monocyclic, bicyclic aryl and heteroaryl compounds,
- and quinazoline derivatives.

7. A method according to claim 4, wherein said inhibitor is selected from the group consisting of N-phenyl-2-pyrimidine-amine derivatives having the formula II :


10



Wherein R1, R2 and R3 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl or a cyclic or heterocyclic group, especially a pyridyl group;

- 15 R4, R5 and R6 are independently chosen from H, F, Cl, Br, I, a C1-C5 alkyl, especially a methyl group;

and R7 is a phenyl group bearing at least one substituent, which in turn possesses at least one basic site, such as an amino function, preferably the following group :



20

8. A method according to claim 7, wherein said inhibitor is the 4-(4-méthylpipérazine-1-ylméthyl)-N-[4-méthyl-3-(4-pyridine-3-yl)pyrimidine-2 ylamine]phényl]-benzamide.

WO 03/039550

PCT/IB02/04330

21

9. A method according to one of claims 3 to 6, wherein said c-kit inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

5

10. A method according to one of claims 3 to 9, wherein said c-kit inhibitor is an inhibitor of activated c-kit.

11. A method according to one of claims 3 to 9, wherein said activated c-kit inhibitor is capable of inhibiting SCF-activated c-kit.

10

12. A method according to claim 10, wherein said inhibitor is capable of inhibiting constitutively activated-mutant c-kit.

13. A method for whitening human skin and treating melanocyte dysfunction associated diseases, comprising administering to a human in need of such treatment a compound that is a selective, potent and non toxic inhibitor of activated c-kit obtainable by a screening method which comprises :

15

a) bringing into contact (i) activated c-kit and (ii) at least one compound to be tested; under conditions allowing the components (i) and (ii) to form a complex,

20

b) selecting compounds that inhibit activated c-kit,

c) testing and selecting a subset of compounds identified in step b), which are unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

14. A method according to claim 13, wherein the screening method further comprises the step consisting of testing and selecting a subset of compounds identified in step b) that are inhibitors of mutant activated c-kit, which are also capable of inhibiting SCF-activated c-kit wild.

25

WO 03/039550

PCT/IB02/04330

22

15. A method according to claim 13, wherein activated c-kit is SCF-activated c-kit wild in step a).
- 5 16. A method according to one of claims 13 to 15, wherein putative inhibitors are tested at a concentration above 10  $\mu$ M in step a).
17. A method according to one of claims 13 to 16, wherein IL-3 is preferably present in the culture media of IL-3 dependent cells at a concentration comprised between 0.5 and  
10 10 ng/ml, preferably between 1 to 5 ng/ml.
18. A method according to one of claims 13 to 16, wherein IL-3 dependent cells are selected from the group consisting of mast cells, transfected mast cells, BaF3, and IC-2.
- 15 19. A method according to one of claims 13 to 18, wherein the extent to which component (ii) inhibits activated c-kit is measured *in vitro* or *in vivo*.
20. A method according to one of claims 13 to 19, further comprising the step consisting of testing and selecting compounds capable of inhibiting c-kit wild at concentration  
20 below 1  $\mu$ M.
21. A method according to claim 20, wherein the testing is performed *in vitro* or *in vivo*.
22. A method according to one of claims 13 to 21, wherein the inhibition of mutant-  
25 activated c-kit and/or c-kit wild is measured using standard biochemical techniques such as immunoprecipitation and western blot.

WO 03/039550

PCT/IB02/04330

23

23. A method according to one of claims 13 to 22, wherein the amount of c-kit phosphorylation is measured.

24. A method according to one of claims 13 to 23, wherein identified and selected  
5 compounds are potent, selective and non-toxic c-kit wild inhibitors.

25. A method for whitening human skin and treating melanocyte dysfunction associated diseases, comprising administering to a human in need of such treatment a c-kit inhibitor obtainable by a screening method comprising :

- 10 a) performing a proliferation assay with cells expressing a mutant c-kit (for example in the transphosphorylase domain), which mutant is a permanent activated c-kit, with a plurality of test compounds to identify a subset of candidate compounds targeting activated c-kit, each having an  $IC_{50} < 10 \mu M$ , by measuring the extent of cell death,
- b) performing a proliferation assay with cells expressing c-kit wild said subset of  
15 candidate compounds identified in step (a), said cells being IL-3 dependent cells cultured in presence of IL-3, to identify a subset of candidate compounds targeting specifically c-kit,
- c) performing a proliferation assay with cells expressing c-kit, with the subset of compounds identified in step b) and selecting a subset of candidate compounds targeting  
20 c-kit wild, each having an  $IC_{50} < 10 \mu M$ , preferably an  $IC_{50} < 1 \mu M$ , by measuring the extent of cell death.

26. A method according to claim 25, wherein the extent of cell death is measured by  $^3H$  thymidine incorporation, the trypan blue exclusion method or flow cytometry with  
25 propidium iodide.

27. A method according to one of claims 1 to 26 for whitening human skin and treating melanocyte dysfunction associated diseases, including hypermelanosis resulting from



WO 03/039550

PCT/IB02/04330

24

melanocyte dysfunction such as lentigines, solar and senile lentigo, Dubreuilh melanosis, moles as well as melanomas, including malignant melanomas.

28. Use of a c-kit inhibitor to manufacture a medicament or a cosmetic composition for  
5 whitening human skin and treating melanocyte dysfunction associated diseases, including hypermelanosis resulting from melanocyte dysfunction such as lentigines, solar and senile lentigo, Dubreuilh melanosis, moles as well as malignant melanomas.

29. A composition suitable for oral or topical administration comprising a tyrosine  
10 kinase inhibitor, more particularly a c-kit inhibitor for whitening human skin and treating melanocyte dysfunction associated diseases, including hypermelanosis resulting from melanocyte dysfunction such as lentigines, solar and senile lentigo, Dubreuilh melanosis, moles as well as malignant melanomas.

15 30. A pharmaceutical or cosmetic composition according to claim 29, which is suitable for topical application.

31. A composition according to claim 30, which is in the form of a gel, paste, ointment, cream, lotion, liquid suspension aqueous, aqueous-alcoholic or, oily solutions, or  
20 dispersions of the lotion or serum type, or anhydrous or lipophilic gels, or emulsions of liquid or semi-solid consistency of the milk type, obtained by dispersing a fatty phase in an aqueous phase or vice versa, or of suspensions or emulsions of soft, semi-solid consistency of the cream or gel type, or alternatively of microemulsions, of microcapsules, of microparticles or of vesicular dispersions to the ionic and/or nonionic  
25 type.

32. A composition according to claim 30, which comprises at least one ingredient selected from hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active

WO 03/039550

PCT/IB02/04330

25

agents, emollients, viscosity enhancing polymers, humectants, surfactants, preservatives, antioxidants, solvents, and fillers.

33. A composition according to claim 30, which is formulated for the delivery of the  
5 tyrosine kinase inhibitor to the skin.

WO 03/039550

PCT/IB02/04330

1/4

## SEQUENCE LISTING

&lt;110&gt; AB Science

&lt;120&gt; Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases

&lt;130&gt; D19833 NT

&lt;150&gt; US 60/323,312

&lt;151&gt; 2001-09-20

&lt;160&gt; 5

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 976

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;223&gt; Human c-kit

&lt;400&gt; 1

Met Arg Gly Ala Arg Gly Ala Trp Asp Phe Leu Cys Val Leu Leu Leu  
1 5 10 15Leu Leu Arg Val Gln Thr Gly Ser Ser Gln Pro Ser Val Ser Pro Gly  
20 25 30Glu Pro Ser Pro Pro Ser Ile His Pro Gly Lys Ser Asp Leu Ile Val  
35 40 45Arg Val Gly Asp Glu Ile Arg Leu Leu Cys Thr Asp Pro Gly Phe Val  
50 55 60Lys Trp Thr Phe Glu Ile Leu Asp Glu Thr Asn Glu Asn Lys Gln Asn  
65 70 75 80Glu Trp Ile Thr Glu Lys Ala Glu Ala Thr Asn Thr Gly Lys Tyr Thr  
85 90 95Cys Thr Asn Lys His Gly Leu Ser Asn Ser Ile Tyr Val Phe Val Arg  
100 105 110Asp Pro Ala Lys Leu Phe Leu Val Asp Arg Ser Leu Tyr Gly Lys Glu  
115 120 125Asp Asn Asp Thr Leu Val Arg Cys Pro Leu Thr Asp Pro Glu Val Thr  
130 135 140Asn Tyr Ser Leu Lys Gly Cys Gln Gly Lys Pro Leu Pro Lys Asp Leu  
145 150 155 160Arg Phe Ile Pro Asp Pro Lys Ala Gly Ile Met Ile Lys Ser Val Lys  
165 170 175Arg Ala Tyr His Arg Leu Cys Leu His Cys Ser Val Asp Gln Glu Gly  
180 185 190Lys Ser Val Leu Ser Glu Lys Phe Ile Leu Lys Val Arg Pro Ala Phe  
195 200 205Lys Ala Val Pro Val Val Ser Val Ser Lys Ala Ser Tyr Leu Leu Arg  
210 215 220

WO 03/039550

PCT/IB02/04330

2/4

Glu 225	Gly	Glu	Glu	Phe	Thr 230	Val	Thr	Cys	Thr	Ile 235	Lys	Asp	Val	Ser	Ser 240
Ser	Val	Tyr	Ser	Thr 245	Trp	Lys	Arg	Glu	Asn 250	Ser	Gln	Thr	Lys	Leu 255	Gln
Glu	Lys	Tyr	Asn 260	Ser	Trp	His	His	Gly 265	Asp	Phe	Asn	Tyr	Glu 270	Arg	Gln
Ala	Thr	Leu 275	Thr	Ile	Ser	Ser	Ala 280	Arg	Val	Asn	Asp	Ser 285	Gly	Val	Phe
Met	Cys 290	Tyr	Ala	Asn	Asn	Thr 295	Phe	Gly	Ser	Ala	Asn 300	Val	Thr	Thr	Thr
Leu 305	Glu	Val	Val	Asp	Lys 310	Gly	Phe	Ile	Asn	Ile 315	Phe	Pro	Met	Ile	Asn 320
Thr	Thr	Val	Phe	Val 325	Asn	Asp	Gly	Glu	Asn 330	Val	Asp	Leu	Ile	Val 335	Glu
Tyr	Glu	Ala	Phe 340	Pro	Lys	Pro	Glu	His 345	Gln	Gln	Trp	Ile	Tyr 350	Met	Asn
Arg	Thr	Phe 355	Thr	Asp	Lys	Trp	Glu 360	Asp	Tyr	Pro	Lys	Ser 365	Glu	Asn	Glu
Ser	Asn 370	Ile	Arg	Tyr	Val	Ser 375	Glu	Leu	His	Leu	Thr 380	Arg	Leu	Lys	Gly
Thr 385	Glu	Gly	Gly	Thr	Tyr 390	Thr	Phe	Leu	Val	Ser 395	Asn	Ser	Asp	Val	Asn 400
Ala	Ala	Ile	Ala	Phe 405	Asn	Val	Tyr	Val	Asn 410	Thr	Lys	Pro	Glu	Ile 415	Leu
Thr	Tyr	Asp	Arg 420	Leu	Val	Asn	Gly	Met 425	Leu	Gln	Cys	Val	Ala 430	Ala	Gly
Phe	Pro	Glu 435	Pro	Thr	Ile	Asp	Trp 440	Tyr	Phe	Cys	Pro	Gly 445	Thr	Glu	Gln
Arg	Cys 450	Ser	Ala	Ser	Val	Leu 455	Pro	Val	Asp	Val	Gln 460	Thr	Leu	Asn	Ser
Ser 465	Gly	Pro	Pro	Phe	Gly 470	Lys	Leu	Val	Val	Gln 475	Ser	Ser	Ile	Asp	Ser 480
Ser	Ala	Phe	Lys	His 485	Asn	Gly	Thr	Val	Glu 490	Cys	Lys	Ala	Tyr	Asn 495	Asp
Val	Gly	Lys	Thr 500	Ser	Ala	Tyr	Phe	Asn 505	Phe	Ala	Phe	Lys	Gly 510	Asn	Asn
Lys	Glu	Gln 515	Ile	His	Pro	His	Thr 520	Leu	Phe	Thr	Pro	Leu 525	Leu	Ile	Gly
Phe 530	Val	Ile	Val	Ala	Gly	Met 535	Met	Cys	Ile	Ile	Val 540	Met	Ile	Leu	Thr
Tyr 545	Lys	Tyr	Leu	Gln	Lys 550	Pro	Met	Tyr	Glu	Val 555	Gln	Trp	Lys	Val	Val 560
Glu	Glu	Ile	Asn	Gly 565	Asn	Asn	Tyr	Val	Tyr 570	Ile	Asp	Pro	Thr	Gln 575	Leu

**PCT/DV02/04330**

Pro	Tyr	Asp	His 580	Lys	Trp	Glu	Phe	Pro 585	Arg	Asn	Arg	Leu	Ser 590	Phe	Gly
Lys	Thr	Leu 595	Gly	Ala	Gly	Ala	Phe 600	Gly	Lys	Val	Val	Glu 605	Ala	Thr	Ala
Tyr	Gly 610	Leu	Ile	Lys	Ser	Asp 615	Ala	Ala	Met	Thr	Val 620	Ala	Val	Lys	Met
Leu 625	Lys	Pro	Ser	Ala	His 630	Leu	Thr	Glu	Arg	Glu 635	Ala	Leu	Met	Ser	Glu 640
Leu	Lys	Val	Leu	Ser 645	Tyr	Leu	Gly	Asn	His 650	Met	Asn	Ile	Val	Asn	Leu
Leu	Gly	Ala	Cys 660	Thr	Ile	Gly	Gly	Pro 665	Thr	Leu	Val	Ile	Thr 670	Glu	Tyr
Cys	Cys	Tyr 675	Gly	Asp	Leu	Leu	Asn 680	Phe	Leu	Arg	Arg	Lys 685	Arg	Asp	Ser
Phe	Ile 690	Cys	Ser	Lys	Gln	Glu 695	Asp	His	Ala	Glu	Ala 700	Ala	Leu	Tyr	Lys
Asn 705	Leu	Leu	His	Ser	Lys 710	Glu	Ser	Ser	Cys	Ser 715	Asp	Ser	Thr	Asn	Glu 720
Tyr	Met	Asp	Met	Lys 725	Pro	Gly	Val	Ser	Tyr 730	Val	Val	Pro	Thr	Lys 735	Ala
Asp	Lys	Arg	Arg 740	Ser	Val	Arg	Ile	Gly 745	Ser	Tyr	Ile	Glu	Arg 750	Asp	Val
Thr	Pro	Ala 755	Ile	Met	Glu	Asp	Asp 760	Glu	Leu	Ala	Leu	Asp 765	Leu	Glu	Asp
Leu	Leu 770	Ser	Phe	Ser	Tyr	Gln 775	Val	Ala	Lys	Gly	Met 780	Ala	Phe	Leu	Ala
Ser 785	Lys	Asn	Cys	Ile	His 790	Arg	Asp	Leu	Ala	Ala 795	Arg	Asn	Ile	Leu	Leu 800
Thr	His	Gly	Arg	Ile 805	Thr	Lys	Ile	Cys	Asp 810	Phe	Gly	Leu	Ala	Arg 815	Asp
Ile	Lys	Asn	Asp 820	Ser	Asn	Tyr	Val	Val 825	Lys	Gly	Asn	Ala	Arg 830	Leu	Pro
Val	Lys	Trp 835	Met	Ala	Pro	Glu	Ser 840	Ile	Phe	Asn	Cys	Val 845	Tyr	Thr	Phe
Glu	Ser 850	Asp	Val	Trp	Ser	Tyr 855	Gly	Ile	Phe	Leu	Trp 860	Glu	Leu	Phe	Ser
Leu 865	Gly	Ser	Ser	Pro	Tyr 870	Pro	Gly	Met	Pro	Val 875	Asp	Ser	Lys	Phe	Tyr 880
Lys	Met	Ile	Lys	Glu 885	Gly	Phe	Arg	Met	Leu 890	Ser	Pro	Glu	His	Ala 895	Pro
Ala	Glu	Met	Tyr 900	Asp	Ile	Met	Lys	Thr 905	Cys	Trp	Asp	Ala	Asp 910	Pro	Leu
Lys	Arg	Pro 915	Thr	Phe	Lys	Gln	Ile 920	Val	Gln	Leu	Ile	Glu 925	Lys	Gln	Ile

WO 03/039550

PCT/IB02/04330

4/4

Ser Glu Ser Thr Asn His Ile Tyr Ser Asn Leu Ala Asn Cys Ser Pro  
 930 935 940

Asn Arg Gln Lys Pro Val Val Asp His Ser Val Arg Ile Asn Ser Val  
 945 950 955 960

Gly Ser Thr Ala Ser Ser Ser Gln Pro Leu Leu Val His Asp Asp Val  
 965 970 975

<210> 2  
 <211> 30  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> Primer

<400> 2  
 aagaagagat ggtacctga ggggtgaccc 30

<210> 3  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> Primer

<400> 3  
 ctgcttcgcg gccgcgttaa ctcttctcaa cca 33

<210> 4  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> Primer

<400> 4  
 agctcgttta gtgaaccgtc 20

<210> 5  
 <211> 20  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <223> Primer

<400> 5  
 gtcagacaaa atgatgcaac 20

## INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/IB 02/04330

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/506 A61P17/00 A61P35/00 A61P43/00 A61K7/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, MEDLINE, CHEM ABS Data, EMBASE, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GRICHNIK JM, BURCH JA, BURCHETTE J, SHEA CR: "The SCF/KIT Pathway Play a Critical Role in the Control of Normal Human Melanocyte Homeostasis" J INVEST DERMATOL, vol. 111, no. 2, 1998, pages 233-238, XP001133837 cited in the application abstract page 237, left-hand column, paragraph 2 -page 238, left-hand column, paragraph 1 --- -/--	1-6, 9-12, 27-33

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*8\* document member of the same patent family

Date of the actual completion of the international search

31 January 2003

Date of mailing of the international search report

07/02/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Langer, O

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/04330

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 03854 A (NOVARTIS ERFind VERWALT GMBH ;NOVARTIS AG (CH); BUERGER HANS MICHA) 28 January 1999 (1999-01-28)	29-33
Y	abstract	1-12, 27, 28
	page 3, paragraph 4 - paragraph 5 page 4, paragraph 3 formulae I and II on page 3 -page 4 page 9, paragraph 3 -page 11, paragraph 1 page 12, paragraph 2 -page 16, paragraph 3 page 17, paragraph 1 claims 10-12	
X	WO 01 47950 A (UNIV GENEVE ;IMHOF BEAT A (CH); WEHRLE HALLER BERNHARD M (CH)) 5 July 2001 (2001-07-05)	1-6, 9-12, 27-33
	page 1, paragraph 3 page 2, paragraph 4 page 3, paragraph 2 - paragraph 3 page 6, paragraph 5 -page 7, paragraph 1 page 34, paragraph 3 -page 35, paragraph 4 claims 51,60	
Y	page 3, paragraph 2	7,8
Y	WO 00 09098 A (NOVARTIS ERFind VERWALT GMBH ;NOVARTIS AG (CH); WOOD JEANETTE MARJ) 24 February 2000 (2000-02-24)	7,8
	page 12, line 5 - line 7 page 12, line 14 - line 15 table 1	
X	EP 0 564 409 A (CIBA GEIGY AG) 6 October 1993 (1993-10-06)	29-33
	claims 1,9-11	
Y	abstract	1-12, 27, 28
	page 3, line 58 -page 4, line 5 page 5, line 1 -page 5 page 5, line 39,6,49 page 16; example 21	
X	& US 5 521 184 A 28 May 1996 (1996-05-28)	1-12, 27-33
	claims 1,23	
X	US 5 886 020 A (TANG PENG CHO ET AL) 23 March 1999 (1999-03-23)	1-6,9-12
	column 2, line 25 - line 37 column 8, line 50 - line 64	
	--- -/--	



## INTERNATIONAL SEARCH REPORT

Int. Patent Application No.  
PC1/IB 02/04330

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>HACHIYA A ET AL: "The inhibitory effect of an extract of clove (Syzygium aromaticum (L.) Merr. et Perry) on ultraviolet B-induced pigmentation via inhibition of stem cell factor/c-kit signaling." JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 119, no. 1, July 2002 (2002-07), page 341 XP008012338 63rd Annual Meeting of the Society for Investigative Dermatology; Los Angeles, California, USA; May 15-18, 2002, July, 2002 ISSN: 0022-202X the whole document</p> <p>---</p>	1-6, 9-12, 27-33
P,X	<p>HATTORI H ET AL: "The role of the epidermal stem cell factor (SCF)/c-kit cascade in the hyperpigmentation mechanism of lentigo senilis (LS)." PIGMENT CELL RESEARCH, vol. 15, no. Supplement 9, 2002, page 58 XP001133846 XVIII International Pigment Cell Conference; Egmond aan Zee, Netherlands; September 09-13, 2002, 2002 ISSN: 0893-5785 the whole document</p> <p>---</p>	1-6, 9-12, 27-33
P,X	<p>IMOKAWA G: "Paracrine cytokine mechanisms of epidermal hyperpigmentation in UVB-melanosis, lentigo senilis and dermatofibroma." PIGMENT CELL RESEARCH, vol. 15, no. Supplement 9, 2002, page 34 XP001133844 XVIII International Pigment Cell Conference; Egmond aan Zee, Netherlands; September 09-13, 2002, 2002 ISSN: 0893-5785 the whole document</p> <p>-----</p>	1-6, 9-12, 27-33

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB 02/04330

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1-27 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 13-26  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 13-26

(A) Claims 13-26 encompass the use of a genus of compounds defined only by their function wherein the relationship between the structural features of the members of the genus and said function has not been defined. In the absence of such a relationship either disclosed in the as-filed application or recognisable by one skilled in the art based upon information readily available, the skilled artisan would not know how to make and use compounds that lack a structural definition. The fact that one could have assayed a compound of interest using the claimed assays does not overcome this defect since one would have no knowledge beforehand as to whether or not any given compound (other than those that might be particularly disclosed in an application) would fall within the scope of what is claimed. It would require undue experimentation (be an undue burden) to randomly screen undefined compounds for the claimed activity. Therefore no search has been performed for claims 13-26, and 27 as far as dependent from 13-26 (Article 5 and 6 PCT).

(B) Present claims 1-12, and 27-33 relate to a rather elevated number of compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds for which a medical use is claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

(C) Present claims 1-12, and 27-33 relate to compounds/uses defined by functional characteristics, namely

- (1) 'tyrosine kinase inhibitor',
- (2) 'c-kit inhibitor', 'inhibitor of activated c-kit', 'c-kit inhibitor (...) capable of inhibiting SCF-activated c-kit', 'inhibitor (...) capable of inhibiting constitutively activated-mutant c-kit',
- (3) 'indolinones', 'pyrimidine derivatives', 'pyrrolopyrimidine derivatives', 'quinazoline derivatives', 'quinoxaline derivatives', 'pyrazoles derivatives', 'bis monocyclic, bicyclic or heterocyclic aryl compounds', 'vinylene-aza-indole derivatives', 'pyridyl quinolones derivatives', 'styryl compounds', 'styryl-substituted pyridyl compounds', 'selenoindoles', 'selenides', 'tricyclic polyhydroxylic compounds', 'benzylphosphonic acid compounds',
- (4) 'N-phenyl-2-pyrimidine-amine derivatives', 'indolinone derivatives', 'pyrrol-substituted indolinones', 'monocyclic, bicyclic aryl and heteroaryl compounds',

The claims cover all compounds/uses falling under the above functional definitions, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds/uses.

Due to the choice of a functional definition of the compounds/uses of the

International Application No. PCT/IB 02 04330

## FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

present application it is impossible to compare them with compounds/uses in the prior art for the full range of compounds/uses claimed.

(D) Present claims 1-12, and 27-33 relate to the treatment of 'melanocyte dysfunction associated diseases'.

The claims cover all medical uses falling under the above etiological definition, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such medical uses. Due to the choice of a functional definition of the medical uses of the present application it is impossible to compare them with medical uses in the prior art for the full range of uses claimed.

(E) The desiderata in claims 2 and 9 that the tyrosine kinase inhibitor/c-kit inhibitor "is unable to promote death of IL-3 dependent cells cultured in the presence of IL-3" have been disregarded.

(F) Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely for the use of compounds of formula (II), in particular CGP57148B, for the manufacture of a medicament for whitening the human skin and for those medical uses that have been explicitly disclosed, namely hypermelanosis resulting from lentigines, solar and senile lentigo, Dubreuilh melanosis, moles and malignant melanomas and for compositions comprising tyrosine kinase compounds of formula (II), including CGP57148B, all with due regard to the inventive concept underlying the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## INTERNATIONAL SEARCH REPORT

Int. Application No.  
PCT/IB 02/04330

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9903854	A	28-01-1999	AU 740713 B2	15-11-2001
			AU 8975998 A	10-02-1999
			BR 9810920 A	15-08-2000
			CN 1264375 T	23-08-2000
			WO 9903854 A1	28-01-1999
			EP 0998473 A1	10-05-2000
			HU 0003230 A2	28-06-2001
			JP 3276359 B2	22-04-2002
			JP 2001510192 T	31-07-2001
			NO 20000227 A	17-01-2000
			NZ 502295 A	21-12-2001
			PL 338129 A1	25-09-2000
			SK 432000 A3	12-06-2000
			TR 200000060 T2	21-09-2000
			US 2002115858 A1	22-08-2002
			ZA 9806362 A	22-01-1999
WO 0147950	A	05-07-2001	AU 2511901 A	09-07-2001
			WO 0147950 A2	05-07-2001
			EP 1240196 A2	18-09-2002
WO 0009098	A	24-02-2000	AU 5733099 A	06-03-2000
			WO 0009098 A2	24-02-2000
			EP 1105136 A2	13-06-2001
			JP 2002522475 T	23-07-2002
EP 0564409	A	06-10-1993	AT 188964 T	15-02-2000
			AU 3569493 A	07-10-1993
			BR 1100739 A3	06-06-2000
			CA 2093203 A1	04-10-1993
			CN 1077713 A ,B	27-10-1993
			CZ 9300560 A3	16-02-1994
			DE 59309931 D1	24-02-2000
			DK 564409 T3	19-06-2000
			EP 0564409 A1	06-10-1993
			ES 2142857 T3	01-05-2000
			FI 931458 A	04-10-1993
			GR 3032927 T3	31-07-2000
			HU 64050 A2	29-11-1993
			IL 105264 A	11-04-1999
			JP 2706682 B2	28-01-1998
			JP 6087834 A	29-03-1994
			KR 261366 B1	01-08-2000
			MX 9301929 A1	29-07-1994
			NO 931283 A	04-10-1993
			NZ 247299 A	26-07-1995
			PT 564409 T	30-06-2000
			RU 2125992 C1	10-02-1999
			SG 43859 A1	14-11-1997
			SK 28093 A3	06-04-1994
			US 5521184 A	28-05-1996
			ZA 9302397 A	04-10-1993
US 5886020	A	23-03-1999	US 5880141 A	09-03-1999
			US 2002102608 A1	01-08-2002
			AT 200863 T	15-05-2001
			AU 706597 B2	17-06-1999
			AU 6044196 A	30-12-1996

## INTERNATIONAL SEARCH REPORT

Int. Patent Application No

PCT/IB 02/04330

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5886020	A	BR 9606410 A	30-12-1997
		CA 2192797 A1	19-12-1996
		DE 29623744 U1	30-09-1999
		DE 69612649 D1	07-06-2001
		DE 69612649 T2	31-10-2001
		DK 769947 T3	13-08-2001
		EP 0769947 A1	02-05-1997
		EP 0934931 A2	11-08-1999
		ES 2159741 T3	16-10-2001
		GR 3036315 T3	31-10-2001
		HU 9701694 A2	28-06-1999
		JP 2000026412 A	25-01-2000
		JP 10504323 T	28-04-1998
		JP 3231044 B2	19-11-2001
		NO 965377 A	12-02-1997
		NZ 310109 A	28-01-1999
		PT 769947 T	31-10-2001
		WO 9640116 A1	19-12-1996
		US 6225335 B1	01-05-2001
		US 6316635 B1	13-11-2001
		US 5792783 A	11-08-1998
		US 5883116 A	16-03-1999
		US 5834504 A	10-11-1998
		US 5883113 A	16-03-1999
		US 2001027207 A1	04-10-2001